整合式心理健康视频会诊模式对基层抑郁焦虑患者的随机对照试验
PROVIDE-C 试验在德国 29 家全科诊所纳入 376 名成人抑郁或焦虑患者,随机接受 PROVIDE 整合式视频会诊模式或常规照护。6 个月时 PHQ-ADS 评分改善优于常规照护(差值 -2.4 分,95%CI -4.5 至 -0.4,P=0.02),12 个月效果持续(-2.9 分,95%CI -5.0 至 -0.7,P<0.01),效应量较小,两组均无严重不良事件。
要点
- PROVIDE 模式为患者在全科诊所与异地精神卫生专家进行 5 次实时视频会诊。
- 6 个月抑郁焦虑症状改善优于常规照护,12 个月效果持续。
- 效应量较小,但抑郁焦虑患病率高,人群层面可能累积获益。
核心结论
- PROVIDE 整合式心理健康视频会诊模式较常规照护可小幅降低基层抑郁焦虑患者的症状严重度,短期和长期均有效。
研究设计与样本
- 评估者设盲、多中心随机对照试验(PROVIDE-C),在德国 29 家全科诊所通过一个试验中心远程在线开展。
- 共纳入 376 名 18-81 岁因抑郁或焦虑就诊于全科医生的成人,按 1:1 随机分为 PROVIDE 组(n=187)和常规照护组(n=189)。
主要发现
- 6 个月时 PROVIDE 组 PHQ-ADS 评分较常规照护组多改善 2.4 分(校正均数变化差值 -2.4,95%CI -4.5 至 -0.4,P=0.02)。
- 12 个月时效果持续,PHQ-ADS 评分差值 -2.9(95%CI -5.0 至 -0.7,P<0.01)。
- 两组均未报告严重不良事件。
关键数值与推荐
- PROVIDE 模式包含 5 次实时视频会诊,由患者在全科诊所与异地精神卫生专家进行跨诊断治疗。
- 常规照护由全科医生提供简短咨询、精神药物处方等干预,可能包括也可能不包括转诊精神卫生专家。
- 主要结局为 6 个月时意向性治疗人群中 PHQ-ADS 平均严重度的绝对变化。
临床怎么用
- 基层可考虑为抑郁焦虑患者提供与异地精神卫生专家连接的短程视频会诊模式。
- 该模式为相对低强度治疗,可作为常规照护的补充,效应量较小需结合患者情况个体化选择。
局限性
- 研究在德国全科诊所开展,结果外推至其他卫生体系需谨慎。
- 效应量较小,临床意义需结合人群层面累积影响评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether an integrated mental health video consultation approach (PROVIDE model) can improve symptoms compared with usual care in adults with depression and anxiety disorders attending primary care. DESIGN: Assessor masked, multicentre, randomised controlled trial (PROVIDE-C). SETTING: In 29 primary care practices in Germany, working remotely online from one trial hub. PARTICIPANTS: 376 adults (18-81 years) who presented to their general practitioner (GP) with depression or anxiety, or both. INTERVENTION: Participants were randomised (1:1) to receive the PROVIDE model (n=187) or usual care (n=189). Usual care was provided by GPs through interventions such as brief counselling and psychotropic medication prescriptions and may or may not have included referrals to mental health specialists. The PROVIDE model comprised transdiagnostic treatment provided through five real-time video sessions between the patient at the primary care practice and a mental health specialist at an offsite location. MAIN OUTCOME MEASURES: The primary outcome was the absolute change in the mean severity of depressive and anxiety symptoms measured using the patient health questionnaire anxiety and depression scale (PHQ-ADS) at six months, in the intention-to-treat population. Secondary outcomes, measured at six and 12 months, included PHQ-ADS subscores, psychological distress related to somatic symptoms, recovery, health related quality of life, quality and patient centredness of chronic illness care, and adverse events. RESULTS: Between 24 March 2020 and 23 November 2021, 376 patients were randomised into treatment groups. Mean age was 45 years (standard deviation (SD) 14), 63% of the participants were female, and mean PHQ-ADS-score was 26 points (SD 7.6). Compared with usual care, the PROVIDE intervention led to improvements in severity of depressive and anxiety symptom (adjusted mean change difference in the PHQ-ADS score -2.4 points (95% confidence interval -4.5 to -0.4), P=0.02) at six months. The effects were sustained at 12 months (-2.9 (-5.0 to -0.7), P<0.01). No serious adverse events were reported in either group. CONCLUSIONS: Through relatively low intensity treatment, the PROVIDE model led to a decrease in depressive and anxiety symptoms with small effects in the short and long term. Depression and anxiety disorders are prevalent and therefore the small effect might cumulatively impact on population health in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT04316572.
引用
- Haun MW, Tönnies J, Hartmann M, et al. Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial. BMJ. 2024. PMID: 39322237. doi:10.1136/bmj-2024-079921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。